Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Someone's opinions, if not themselves offensive, should not be met with such offensive responses.
Reminds me of a playground, where any differences to the norm get verbally abused and ridiculed.
You should be ashamed of yourselves.
Bullies, f##king hate bullies.
My gut feeling is that this was suppressed at this level to fill a very large buy with the mm's just hoovering up all the sells from impatient holders and profit takers.
We shall see Monday, if a delayed trade appears once it's been filled.
Can't be long now until the news and the next leg up.
Good luck guys and gals.
Looking back, I can only find the folowing from March 22.
The scientists of Hemogenyx Pharmaceuticals have now developed an initial set of CBRs. One is a CBR to program human immune cells to neutralize the SARS-COV-2 virus. The Company has successfully demonstrated in vitro that immune cells programmed with the CBR against SARS-COV-2 selectively consume a live synthetic virus. Importantly, the function of CBR was not affected by known mutations of the spike protein that endows the SARS-COV-2 virus with the ability to infect cells. In collaboration with an as yet undisclosed partner, the Company is planning in vivo tests to demonstrate that CBR could be used against infectious replicating SARS-COV-2 virus. Work also continues to expand the potential use of CBR into the area of cancer treatment.
Â
Having filed the patent application, Hemogenyx Pharmaceuticals is now able to move CBRs to the point of in vivo trials and will provide updates and more detailed scientific information to shareholders in due course.
Followed by this in Sept:
CBR
Â
We have also made significant progress with CBR, a novel platform technology that constitutes a new paradigm for treating viral infections. The essence of the CBR-based approach is programming immune cells using a novel type of modifiable synthetic receptor to destroy viral pathogens. This approach can also potentially be used to programme immune cells to destroy malignant cells causing certain types of cancer. Our scientists have achieved in vitro proof of concept for a CBR construct that neutralises all known variants of the SARS-CoV-2 virus that causes COVID, and have now completed preparations to test it against live replicating virus in a Biosafety Level 3 facility. The Company has filed a seminal provisional patent application protecting its rights to the intellectual property ("IP") covering CBR.
I can't find any other reference which would give us a better idea of timescale.
TBF PQ3 finishing isn't really a catalyst, third party confirmation that our results comply with a set of required quality attributes should be and any timescales given for IND will also put some urgency into PI's on the fence. Alternatively if any news on CBR lands then all bets are off.
The deferment of the meeting is not causing any delay in the development of the product candidate. In the meantime, the process will be dealt with by written responses by the FDA to a submission which is now being refined. A PRE-IND MEETING WILL THEN BE NECESSARY ONLY IF THE WRITTEN RESPONSES LEAVE ANY MATTERS UNRESOLVED. In light of this written process now implemented by FDA, there is no anticipated impact from the deferment on the IND filing for HEMO-CAR-T.
See capitals from the Pre IND RNS. If Hemo are updating the FDA with all their data, then approval should come pretty swiftly following 3d party confirmation of results.
I can’t imagine the funders cutting and running when they have had a successful outcome at ever legal juncture thus far? I know there would be a case for, quit while you’re ahead but IMHO they have everything to win and very little to lose at this point.
Not really comparable but, I’ve seen a fair few accident claims land on my desk and the claimants solicitors always throw ridiculous figures out.
Could the lower end of the range of expectations simply be lower than the ridiculous figure they put across to the court and have kept up the appearance, of being dissatisfied with the what Samsung are willing to offer, within their RNS?
Just need a rise of 1800% and I can walk away. The pain is real :(
I have recently reinvested here, I was last in and out of this share in the back end of 2020 and I have a vague memory of something being said about the possability of increasing output significantly if they were to expand their facility. I remember a figure of $300k being mentioned for these works but I can't find anything in the rns'. Or there is the possibility that I'm just losing my mind. Does anyone else remember anything like that being said?
I'm 80% down here, got caught up in all the hype last year, and I check in on this board periodically.
You two are like the old grumpy men in the local pub, always piping up with negative comments in other people's conversations. Now the old guys in the pub are there because they're lonely plus the can get beer. You can't get beer on this board so you must be lonely...
Really though, if your not invested here and never will be, wouldn't your time be better spent elsewhere and maybe search for some positivity or god forbid spread some positivity.
Rerate anyone?
So they're predicting future revenue to be usd16m/gbp11.5m per annum for the next 10 years with a current market cap of gbp6m. Bit of a no brained this one.
When it's a TICKet....
Did I miss when this board discussed this feature of the MyGP app? It seems to have been released o the 21st April. How am I only just seeing it now. Kind of puts the final nail in the COV-ID coffin don't you think?